Ann: Trading Halt, page-26

Any chance we have already been given the playbook for this.. ??

https://www.immutep.com/files/content/investor/analyst-report/2021/20210610-Alliance%20Global%20Partners%20-%20Immutep's%20Vindication%20and%20the%20Next%20Chapter%20in%20LAG-3%20Immunotherapy%20%E2%80%94%20PT%20to%20$9%20from%20$6.pdf

“……At this year's ASCO (June 4-8) Immutep's developmentpipeline has landed itself squarely(and in our view favorably) in the midst of several industry hot topics ……………..

…… We believe TACTI-002 data were especially impactful, asmedian PFS findings in bothNSCLC and HNSCC was presented for the first time with results that appear very competitive (as detailed below)— something the Street appears to haveoverlooked in the deluge of ASCO data over the last several days. As a result,we believe there is nowsufficient evidence to warrant the inclusion of revenues for efti + pembro as a frontline treatment option formetastatic NSCLC (where we believe benefits greatest relative to peers) in ourmodel……….”